Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.
View / Open Files
Authors
Bassi, Jessica
Giannini, Olivier
Silacci-Fregni, Chiara
Pertusini, Laura
Hitz, Paolo
Terrot, Tatiana
Franzosi, Yves
Saliba, Christian
Meury, Marcel
Dellota, Exequiel A
Dillen, Josh R
Hernandez, Patrick
Czudnochowski, Nadine
Cameroni, Elisabetta
Beria, Nicola
Ventresca, Mariangela
Badellino, Alberto
Lavorato-Hadjeres, Soraya
Lecchi, Elisabetta
Bonora, Tecla
Mattiolo, Matteo
Trinci, Guido
Garzoni, Daniela
Bonforte, Giuseppe
Forni-Ogna, Valentina
Giunzioni, Davide
Berwert, Lorenzo
Gupta, Ravindra K
Ceschi, Alessandro
Cippà, Pietro
Corti, Davide
Lanzavecchia, Antonio
Publication Date
2022Journal Title
PLoS One
ISSN
1932-6203
Publisher
Public Library of Science (PLoS)
Volume
17
Issue
2
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Bassi, J., Giannini, O., Silacci-Fregni, C., Pertusini, L., Hitz, P., Terrot, T., Franzosi, Y., et al. (2022). Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.. PLoS One, 17 (2) https://doi.org/10.1371/journal.pone.0263328
Description
Funder: Swiss Kidney Foundation
Abstract
Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is required to guide prophylactic and therapeutic COVID-19 interventions in this frail population. By analyzing plasma samples from 130 hemodialysis and 13 peritoneal dialysis patients after two doses of BNT162b2 or mRNA-1273 vaccines, we found that 35% of the patients had low-level or undetectable IgG antibodies to SARS-CoV-2 Spike (S). Neutralizing antibodies against the vaccine-matched SARS-CoV-2 and Delta variant were low or undetectable in 49% and 77% of patients, respectively, and were further reduced against other emerging variants. The fraction of non-responding patients was higher in SARS-CoV-2-naïve hemodialysis patients immunized with BNT162b2 (66%) than those immunized with mRNA-1273 (23%). The reduced neutralizing activity correlated with low antibody avidity. Patients followed up to 7 months after vaccination showed a rapid decay of the antibody response with an average 21- and 10-fold reduction of neutralizing antibodies to vaccine-matched SARS-CoV-2 and Delta variant, which increased the fraction of non-responders to 84% and 90%, respectively. These data indicate that dialysis patients should be prioritized for additional vaccination boosts. Nevertheless, their antibody response to SARS-CoV-2 must be continuously monitored to adopt the best prophylactic and therapeutic strategy.
Keywords
CHO Cells, Animals, Humans, Cricetulus, Immunoglobulin G, Neutralization Tests, Vaccination, Renal Dialysis, Risk Factors, Case-Control Studies, Follow-Up Studies, Antibody Affinity, Dose-Response Relationship, Immunologic, Antibodies, Neutralizing, HEK293 Cells, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines
Sponsorship
MRC (via Imperial College London) (MR/W005611/1)
Identifiers
PMC8830698, 35143540
External DOI: https://doi.org/10.1371/journal.pone.0263328
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334948
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.